
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent oHCM
Phase 3 data show significant reduction in LVOT gradient and a favorable safety profile, positioning Camzyos as a potential first targeted therapy for adolescents with oHCM Bristol Myers Squibb has reported encouraging results from the Phase 3 SCOUT-HCM trial evaluating…












